Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2017 | Avelumab in Merkel Cell Carcinoma – updates from ASCO 2017

Sandra D'Angelo • 3 Jun 2017
ASCO 2017
Skin Cancer Avelumab

Dr Sandra D’Angelo from Memorial Sloan Kettering Cancer Center, New York, gives us an update on the use of avelumab as frontline therapy for patients with Merkel cell carcinoma during ASCO 2017. She describes some of the excitement and experience using immunotherapy in these patients. One year on from initial data presented on avelumab we are learning a lot but further study is warranted as it’s still early days.

More from Sandra D'Angelo

Avelumab and pembrolizumab for the treatment of merkel cell carcinoma
1:36
Avelumab and pembrolizumab for the treatment of merkel cell carcinoma
Sandra D'Angelo • 1 Jun 2017

Related Videos

BRAF/MEK inhibition prior to immunotherapy in melanoma: insights from the COWBOY trial
1:45
BRAF/MEK inhibition prior to immunotherapy in melanoma: insights from the COWBOY trial
Kalijn Bol • 31 May 2026
COWBOY trial: optimal sequencing of BRAF/MEK inhibition and immunotherapy in BRAF-mutated melanoma
1:08
COWBOY trial: optimal sequencing of BRAF/MEK inhibition and immunotherapy in BRAF-mutated melanoma
Kalijn Bol • 31 May 2026
Could induction BRAF/MEK inhibition be useful for some melanoma patients with metastases?
1:02
Could induction BRAF/MEK inhibition be useful for some melanoma patients with metastases?
Kalijn Bol • 31 May 2026
The future of personalized and off-the-shelf mRNA vaccines in melanoma
1:02
The future of personalized and off-the-shelf mRNA vaccines in melanoma
James Smithy • 31 May 2026
The content of VJOncology is intended for healthcare professionals